Since previous studies have demonstrated that another member of the syndecan family, SDC1 modulates the TF pathway in breast cancer [40], and since SDC3 is required for localization of issue-factor-pathway-inhibitor (TFPI) to endothelial-, smooth muscle-, and breast cancer cells [41], we investigated the effect of SDC3 depletion and TFPI treatment on Src activation. Here, SDC3 is linked to breast carcinoma.